Ticagrelor for these high risk patients
• More potent antiplatelets, ie ticagrelor / prasugrel is likely to be a better treatment choice in these patients.
Larsen et al
Objectives of study: 
Uptake of Ticagrelor
• Our study shows a low usage of ticagrelor in overall ACS patients (25%) • Usage of ticagrelor in diabetic subpopulation was significantly lower then the overall ACS population. • There is a trend of ticagrelor use in 'healthier patients' ?
Unfamiliarity with drug causing it to be less used in patients with high bleeding risk ie more comorbidities
Discussion on HPR
• Our study indicates:
• High platelet reactivity remains significant in diabetics and patients of Maori Ethnicity after clopidogrel loading • This may result in increased future cardiovascular events.
• The risk of HPR in Diabetic and Maori population is attenuated by the loading of ticagrelor at presentation with ACS. • There is a clear benefit of ticagrelor over clopidogrel in terms of HPR • This may translate into reduction in MACE events in this populations.
Conclusion
• Ticagrelor prescribing is low in the diabetic population in our cohort.
Reasons of this requires further investigation. • In diabetic and Maori patients on clopidogrel, High Platelet Reactivity persists compared to other ACS patients on clopidogrel. • Awareness of HPR and benefits of ticagrelor may increase prescribing of ticagrelor these population groups.
